Perspectives of Immune Therapy in Coronavirus Disease 2019

Area of Science:

• Immunology
• Virology
• Infectious Diseases

Background:

• Coronavirus disease 2019 (COVID-19) poses a global health challenge, necessitating strategies to bolster immune responses against SARS-CoV-2.
• The human immune system, including antibody production, plays a crucial role in neutralizing SARS-CoV-2 and mitigating multi-organ damage.
• Initial observations of mild COVID-19 in children suggested potential protective cross-reactivity from prior viral infections like measles.

Purpose of the Study:

• To review current immunotherapeutic strategies for COVID-19.
• To explore the potential of antibody-based interventions against SARS-CoV-2.
• To highlight the importance of understanding host antiviral responses for future treatment development.

Main Methods:

• Review of existing literature on immunotherapies for COVID-19.
• Analysis of antibody functions, including neutralization and cross-reactivity.
• Examination of convalescent plasma, intravenous immunoglobulin, and monoclonal antibodies.

Main Results:

• Convalescent plasma has demonstrated virus-neutralizing effects in early-stage SARS-CoV-2 infection.
• The efficacy of convalescent plasma is geographically and temporally limited due to viral variability.
• Intravenous immunoglobulin offers non-specific antiviral and immunomodulatory benefits.
• Human monoclonal antibodies can inhibit SARS-CoV-2 interaction with host cells, preventing tissue injury.

Conclusions:

• Understanding host antiviral responses is key to developing effective immunotherapies for COVID-19.
• Antibody-based strategies, including convalescent plasma and monoclonal antibodies, show potential for managing SARS-CoV-2 infections.
• Further research into host-pathogen interactions will guide the development of future immunotherapeutic approaches against COVID-19.